• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

Como acabar de vez com as doenças negligenciadas?

9 Apr 2025

By Sergio Sosa-Estani, Continental Lead Americas and Latin America Director, DNDi

Dengue, Chagas, leishmaniose… As doenças tropicais negligenciadas (DTNs) afetam, anualmente, mais de 1 milhão de pessoas e fazem mais de 200 mil vítimas fatais, de acordo com a Organização Mundial da Saúde (OMS).

Elas formam um grupo de 21 enfermidades determinadas pela OMS que prevalecem principalmente em áreas de extrema pobreza. As DTNs recebem esse nome porque são ignoradas sobretudo pela indústria farmacêutica privada.

Por atingirem populações vulneráveis, não representam um mercado lucrativo e, assim, não despertam interesse de investimentos em pesquisa e desenvolvimento de novos tratamentos.

O termo “negligenciadas” não se refere apenas às doenças, mas também às pessoas que convivem com elas. Enquanto lidam com dores crônicas e outros sintomas, muitas delas ainda enfrentam o estigma social.

Read the viewpoint published in Veja Saúde

Partnership Chagas disease Cutaneous leishmaniasis Dengue Latin America

Read, watch, share

Loading...
Press releases
27 Jul 2026

DNDi leadership to change in 2027

Stories
16 Jul 2026

Annie Liang: How students’ advocacy helped bring mycetoma out of the shadows

Publications
16 Jul 2026

DNDi 2025 Annual Report

Laboratory of Medicinal and Computational Chemistry (LQMC), São Paulo University USP, São Carlos Campus, São Paulo Brazil.
Press releases
13 Jul 2026

DNDi welcomes continued GHIT support for collaboration on dengue and Zika virus drug discovery with Eisai and new partner, the Japan Institute for Health Security 

Chepokarial Rubben attentively cares for her five-year-old son, Romanu Kiptoo, at the kala-azar ward of Kacheliba Sub-County Referral Hospital in West Pokot County, Kenya. She gently soothes him, offering comfort as he endures the painful treatment for kala-azar.
Press releases
13 Jul 2026

DNDi welcomes GHIT support to advance novel oral drug candidate for leishmaniasis, accelerating progress towards elimination goals

Press releases
8 Jul 2026

Brazil, Malaysia, and Thailand set to start global clinical trial to test promising dengue treatment developed by Serum Institute of India

Patricia, 44, from Area 44 in Lilongwe, Malawi, has lived with vision loss for 10 years following a late diagnosis of cryptococcal meningitis.
Stories
30 Jun 2026

Cryptococcal meningitis: Africa’s neglected HIV killer

News
29 Jun 2026

Eric Easom, Dr Marcus Lacerda, and Mathieu Lamiaux join the DNDi Board of Directors 

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license